Astrotech Developing Screening Instrument for Lung Diseases Including COVID-19/Coronavirus & Pneumonia

星空科技发展肺癌筛查仪器,包括 COVID-19/冠状病毒和肺炎

2020-03-26 01:00:05 BioSpace


AUSTIN, Texas---- Astrotech Corporation [NASDAQ: ASTC] today announced that the BreathTest-1000™ is under development to screen for volatile organic compound metabolites found in a person’s breath that could indicate they may have an infection, including Coronavirus Disease 2019 or the resulting disease, pneumonia. The Company believes that its unique mass spectrometry technology that was initially developed in collaboration with the National Aeronautics and Space Administration , the U.S. Army, and the Transportation Security Administration is ideal for lung disease testing applications, which are now under development. The Astrotech mass spectrometry technology (Technology) was designed to be inexpensive, small, rugged, fast, and easy to use for air quality monitoring and trace detection of chemical warfare agents, explosives, and narcotics. It has also been certified by the European Civil Aviation Conference (ECAC) and is now deployed in air cargo facilities throughout the European Union. The Company believes that the Company’s Technology can be designed as a field-deployed instrument used at drive-up testing facilities to quickly (under 1 min.) and easily (minimal training required) test for the VOCs found in the breath of COVID-19 and pneumonia infected patients. Most reliable testing performed today requires the collection of off-site samples in the field that are then sent to centrally located laboratories for testing. This process requires many days to ship, process, and receive the results, exacerbating the problem while people spread the disease. With the BreathTest-1000™, testing is performed at the point-of-care and the screening results are near-instant. The BreathTest-1000™ is not expected to be as accurate as laboratory DNA testing but could be an excellent quick screening device for field applications. The development of the BreathTest-1000 follows the Company’s announcement on June 15th, 2017, where positive results were reported in pre-clinical trials for the BreathDetect-1000, a rapid bedside breathalyzer that detects bacterial infections in the respiratory tract, including pneumonia. Subject to any necessary regulatory approvals, the Company plans to combine the detection of COVID-19 with the detection of pneumonia into the BreathTest-1000 instrument to provide a near-immediate screening test for symptoms that indicate a person might have COVID-19 or pneumonia. “With the Coronavirus pandemic impacting millions of families around the globe, we are now very focused on the development of a rugged, inexpensive, quick, and easy to use testing platform that can be deployed to thousands of point-of-care locations worldwide, if approved. This is an incredibly scalable solution that is very much needed to screen as many people as possible in the shortest time," stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation. In addition, the Company will be launching a new subsidiary company, BreathTech Corporation, that will hold the exclusive license to use the 1st Detect Technology™ for breath analysis. About Astrotech Corporation Astrotech (NASDAQ: ASTC) is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technology in order to maximize shareholder value. 1st Detect develops, manufactures, and sells explosives trace detectors for use in the security and detection market. AgLAB develops, manufactures, and sells chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Astrotech is headquartered in Austin, Texas. For information, please visit This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, whether we can successfully develop our proprietary technologies and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements. View source version on Eric Stober, Chief Financial Officer, Astrotech Corporation, (512) 485-9530 Source: Astrotech Corporation View this news release online at:
德克萨斯州 AUSTIN ----天体技术公司( NASDAQ : ASTC )今天宣布,正在研制“呼吸测试-1000™”以筛选在人呼吸中发现的挥发性有机化合物代谢产物,这些物质可能表明他们可能有感染,包括2019年的冠状病毒病或由此产生的疾病,肺炎。该公司认为,其独特的质谱技术最初是与国家航空和航天管理局、美国陆军和运输安全管理局合作开发的,是目前正在开发的肺部疾病检测应用的理想选择。 星空科技质谱技术(技术)是设计为廉价、小、坚固、快速、易于使用的空气质量监测和化学战剂、爆炸物和麻醉剂的微量检测。它还得到了欧洲民用航空会议( ECAC )的认证,现已部署在整个欧盟的空运设施中。本公司认为,本公司的技术可以设计为现场部署的仪器,用于驱动测试设施,以快速(不到1分钟)和容易(最少需要培训)的 VOC 测试发现在 COVID-19和肺炎感染患者的呼吸。 今天进行的最可靠的测试需要收集现场以外的样品,然后送到位于中心的实验室进行测试。这个过程需要很多天的时间来运送、处理和接收结果,在人们传播疾病的同时加剧了问题。使用 BreathTest-1000™,在护理点进行测试,筛选结果近乎即时。乳房测试-1000™预计不会像实验室 DNA 测试那样准确,但可能是一个很好的现场应用快速筛选设备。 乳房检测-1000的开发是在本公司于2017年6月15日发布公告后进行的,在呼吸检测-1000的临床前试验中报告了阳性结果,该产品是一种快速的床旁呼吸器,用于检测包括肺炎在内的呼吸道细菌感染。在获得任何必要的监管批准后,公司计划将 COVID-19的检测与肺炎的检测结合到 BreathTest-1000仪器中,为表明人可能患有 COVID-19或肺炎的症状提供近立即的筛查测试。 “随着冠状病毒大流行影响到全球数百万家庭,我们现在非常关注开发一个坚固、廉价、快速、易于使用的测试平台,如果获得批准,可以部署到全球数千个护理点。Astrotech 公司董事长兼首席执行官 Thomas B.PickensIII 说:“这是一个难以置信的可扩展的解决方案,在最短的时间内需要尽可能多的人进行筛选。” 此外,公司还将成立一家新的子公司,即 BreathTech 公司,该公司将拥有使用第一检测技术™进行呼吸分析的独家许可。 关于航天科技公司 Astrotech ( NASDAQ : ASTC )是一家以创新技术为基础,以股东价值最大化为目标,发起、管理和建设可扩展公司的科技开发和商业化公司。第一检测开发、制造和销售用于安全和检测市场的爆炸物跟踪检测器。AgLAB 开发、制造和销售用于农业市场的化学分析仪。呼吸技术公司正在开发一种呼吸分析工具,以提供肺部疾病的早期检测。Astrotech 总部设在德克萨斯州的奥斯汀。有关信息,请访问 。 本新闻稿载有根据1995年《私人证券诉讼改革法案》安全港条款所作的前瞻性陈述。该等前瞻性陈述受可能导致实际结果与前瞻性声明存在重大差异的风险、趋势及不确定因素影响。这些因素包括但不限于,我们能否成功开发我们的专有技术,市场是否接受我们的产品和服务,以及公司证券交易委员会备案文件(包括10-K 表格中的年度报告)中描述的其他风险因素和业务考虑。本文件中的任何前瞻性陈述都应根据这些重要的风险因素进行评估。本公司不承担更新这些前瞻性陈述的义务。 查看 businesswire 上的源代码。网站: Eric Stober , Astrotech 公司首席财务官,(512)485-9530 资料来源:航天科技公司 在线查看本新闻稿,网址为: